• HOME
  • NEWS
  • EXPLORE
    • CAREER
      • Companies
      • Jobs
    • EVENTS
    • iGEM
      • News
      • Team
    • PHOTOS
    • VIDEO
    • WIKI
  • BLOG
  • COMMUNITY
    • FACEBOOK
    • INSTAGRAM
    • TWITTER
Tuesday, November 18, 2025
BIOENGINEER.ORG
No Result
View All Result
  • Login
  • HOME
  • NEWS
  • EXPLORE
    • CAREER
      • Companies
      • Jobs
        • Lecturer
        • PhD Studentship
        • Postdoc
        • Research Assistant
    • EVENTS
    • iGEM
      • News
      • Team
    • PHOTOS
    • VIDEO
    • WIKI
  • BLOG
  • COMMUNITY
    • FACEBOOK
    • INSTAGRAM
    • TWITTER
  • HOME
  • NEWS
  • EXPLORE
    • CAREER
      • Companies
      • Jobs
        • Lecturer
        • PhD Studentship
        • Postdoc
        • Research Assistant
    • EVENTS
    • iGEM
      • News
      • Team
    • PHOTOS
    • VIDEO
    • WIKI
  • BLOG
  • COMMUNITY
    • FACEBOOK
    • INSTAGRAM
    • TWITTER
No Result
View All Result
Bioengineer.org
No Result
View All Result
Home NEWS Science News Health

Topical solution may be less toxic option for patients with noncancerous skin growth

Bioengineer by Bioengineer
March 29, 2018
in Health
Reading Time: 3 mins read
0
Share on FacebookShare on TwitterShare on LinkedinShare on RedditShare on Telegram

WASHINGTON (March 29, 2018) — Seborrheic keratosis is the most common noncancerous skin growth in adults seen by doctors in everyday practice. While it can look like skin cancer, seborrheic keratosis is not thought to be caused by sun-related exposure, in fact, the cause is unclear. It typically presents as a brown or black growth on the face, chest, shoulders, or back.

Currently, the most commonly employed treatment of seborrheic keratosis is cryosurgery, the local application of intense cold to destroy unwanted tissue. The procedure has a number of post-operative side effects ranging from scarring and blistering to pigment change most notable in dark skin types.

To better understand the biological consequences of cryosurgery on pigment cells in the skin and the potential for new approaches that can potentially overcome these limitations, a team of researchers at the George Washington University (GW) School of Medicine and Health Sciences compared the toxicological impact of cryosurgery with an FDA-approved topical 40 percent hydrogen peroxide solution (A-101) for the treatment of seborrheic keratosis, in human skin equivalents derived from darker skin types. The findings were recently published in the Journal of the American Academy of Dermatology.

"Given the common nature of these growths and the frequency with which patients seek treatment for them, we wanted to clearly demonstrate at the cellular level the degree of injury, and most importantly, pigmentary changes, from both the gold standard cryosurgery and a newly approved approach, A-101 topical solution," said Adam Friedman, MD, associate professor of dermatology at the GW School of Medicine and Health Sciences and senior author of the study. "A-101 was found to be less cytotoxic, or toxic to living cells, and less damaging to melanocytes, the cells in the skin that make pigment, than cryosurgery."

In order to predict the toxicological impacts of cryosurgery and the A-101 treatment, the team evaluated skin architecture, metabolic activity, and cytotoxicity, with emphasis on melanocytes. The results of the study show that cryosurgery is a more cytotoxic treatment than A-101 for seborrheic keratosis, which suggests that A-101 could be a safer option for removal of seborrheic keratosis that reduces the risk of post-operative pigment change.

"There is ongoing clinical work evaluating the safety of this solution in darker skin types," said Friedman. "Another important take away from this study is to also recognize how damaging even a small amount of cryotherapy, a five-second free time, can be to human skin. These findings should be considered when using for the broad array of skin diseases for which cryosurgery is warranted.

###

The study, titled "An Ex-vivo Evaluation of Cytotoxicity and Melanocyte Viability after A-101 Hydrogen Peroxide Topical Solution 40% or Cryosurgery Treatment in Seborrheic Keratosis Lesions" can be found at https://www.sciencedirect.com/science/article/pii/S0190962218304882.

Media: To interview Dr. Friedman, contact Ashley Rizzardo at [email protected] or 202-994-8679.

About the GW School of Medicine and Health Sciences: Founded in 1824, the GW School of Medicine and Health Sciences (SMHS) was the first medical school in the nation's capital and is the 11th oldest in the country. Working together in our nation's capital, with integrity and resolve, the GW SMHS is committed to improving the health and well-being of our local, national and global communities. smhs.gwu.edu

Media Contact

Ashley Rizzardo
[email protected]
202-994-8679
@GWtweets

http://www.gwu.edu

https://smhs.gwu.edu/news/topical-solution-may-be-less-toxic-option-patients-noncancerous-skin-growth

Related Journal Article

http://dx.doi.org/10.1016/j.jaad.2018.03.034

Share14Tweet7Share2ShareShareShare1

Related Posts

Ferroptosis: A Key Player in Sepsis Progression

November 18, 2025

Exploring ICU Nurses’ Innovation Drivers via Random Forest

November 18, 2025

Glucagon-Like Peptide-1 Agonist Withdrawal Impacts Revealed

November 18, 2025

Hydralazine: Promising Epigenetic Treatment for Psoriasis?

November 18, 2025
Please login to join discussion

POPULAR NEWS

  • ESMO 2025: mRNA COVID Vaccines Enhance Efficacy of Cancer Immunotherapy

    211 shares
    Share 84 Tweet 53
  • New Research Unveils the Pathway for CEOs to Achieve Social Media Stardom

    201 shares
    Share 80 Tweet 50
  • Scientists Uncover Chameleon’s Telephone-Cord-Like Optic Nerves, A Feature Missed by Aristotle and Newton

    118 shares
    Share 47 Tweet 30
  • Neurological Impacts of COVID and MIS-C in Children

    89 shares
    Share 36 Tweet 22

About

We bring you the latest biotechnology news from best research centers and universities around the world. Check our website.

Follow us

Recent News

Ferroptosis: A Key Player in Sepsis Progression

Exploring ICU Nurses’ Innovation Drivers via Random Forest

Glucagon-Like Peptide-1 Agonist Withdrawal Impacts Revealed

Subscribe to Blog via Email

Enter your email address to subscribe to this blog and receive notifications of new posts by email.

Join 69 other subscribers
  • Contact Us

Bioengineer.org © Copyright 2023 All Rights Reserved.

Welcome Back!

Login to your account below

Forgotten Password?

Retrieve your password

Please enter your username or email address to reset your password.

Log In
No Result
View All Result
  • Homepages
    • Home Page 1
    • Home Page 2
  • News
  • National
  • Business
  • Health
  • Lifestyle
  • Science

Bioengineer.org © Copyright 2023 All Rights Reserved.